Headlines about Nabriva Therapeutics (NASDAQ:NBRV) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nabriva Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.7201104639785 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of research analysts have commented on the company. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price (up previously from $15.00) on shares of Nabriva Therapeutics in a research note on Tuesday, September 19th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Nabriva Therapeutics in a research note on Tuesday, September 19th. Wedbush reiterated an “outperform” rating and set a $21.00 price target (up previously from $13.00) on shares of Nabriva Therapeutics in a research note on Monday, September 18th. Leerink Swann reiterated an “outperform” rating and set a $22.00 price target (up previously from $20.00) on shares of Nabriva Therapeutics in a research note on Monday, September 18th. Finally, Zacks Investment Research upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target for the company in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $18.61.
Nabriva Therapeutics (NASDAQ NBRV) traded down $0.03 on Friday, hitting $6.18. The stock had a trading volume of 74,222 shares, compared to its average volume of 263,298. The company has a market cap of $227.85 and a P/E ratio of -0.24. Nabriva Therapeutics has a 52 week low of $4.75 and a 52 week high of $14.10.
TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-nabriva-therapeutics-nbrv-stock-price.html.
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.